iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Hits New 52-Week High – Here’s What Happened

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $103.77 and last traded at $103.69, with a volume of 88422 shares trading hands. The stock had previously closed at $102.38.

iShares U.S. Pharmaceuticals ETF Stock Performance

The business has a 50 day moving average of $95.65 and a two-hundred day moving average of $90.43. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 17.75 and a beta of 0.49.

Hedge Funds Weigh In On iShares U.S. Pharmaceuticals ETF

A number of institutional investors have recently modified their holdings of IHE. EFG International AG acquired a new stake in iShares U.S. Pharmaceuticals ETF in the 4th quarter valued at $38,000. Assetmark Inc. lifted its stake in shares of iShares U.S. Pharmaceuticals ETF by 203.9% in the fourth quarter. Assetmark Inc. now owns 465 shares of the company’s stock valued at $39,000 after buying an additional 312 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of iShares U.S. Pharmaceuticals ETF by 35.0% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock valued at $39,000 after buying an additional 120 shares in the last quarter. Blueline Advisors LLC acquired a new position in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at about $41,000. Finally, Accent Capital Management LLC acquired a new position in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at about $42,000.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.